Search details
1.
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
Haematologica
; 2024 Apr 04.
Article
in English
| MEDLINE | ID: mdl-38572567
2.
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood
; 137(19): 2634-2645, 2021 05 13.
Article
in English
| MEDLINE | ID: mdl-33211842
3.
Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation.
Haematologica
; 108(3): 785-796, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-35586966
4.
Psychosis secondary to thyrotoxicosis that persisted post-thyroidectomy: a case report.
BMC Psychiatry
; 23(1): 750, 2023 10 13.
Article
in English
| MEDLINE | ID: mdl-37833705
5.
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
Br J Haematol
; 197(5): 558-572, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35191541
6.
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Br J Haematol
; 198(3): 492-502, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35485402
7.
Oxymetazoline vs ofloxacin vs ciprofloxacin/dexamethasone- effects of drops on tympanostomy tube postoperative otorrhea.
Am J Otolaryngol
; 43(6): 103580, 2022.
Article
in English
| MEDLINE | ID: mdl-36055060
8.
Electrochemistry of redox-active molecules confined within narrow carbon nanotubes.
Chem Soc Rev
; 50(19): 10895-10916, 2021 Oct 04.
Article
in English
| MEDLINE | ID: mdl-34396376
9.
Safety of decreasing ureteral stent duration following radical cystectomy.
World J Urol
; 39(2): 473-479, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-32303901
10.
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real-World Experience from 554 sequential core biopsies from a single centre.
Eur J Haematol
; 106(2): 267-272, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33159689
11.
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012).
Br J Haematol
; 189(1): 128-132, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31710702
12.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
N Engl J Med
; 377(14): 1331-1344, 2017 10 05.
Article
in English
| MEDLINE | ID: mdl-28976863
13.
The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells.
Haematologica
; 105(6): 1593-1603, 2020 06.
Article
in English
| MEDLINE | ID: mdl-31537685
14.
The role of obinutuzumab in the management of follicular lymphoma.
Future Oncol
; 15(31): 3565-3578, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31538821
15.
In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia.
Haematologica
; 103(3): 497-505, 2018 03.
Article
in English
| MEDLINE | ID: mdl-29242301
16.
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
Br J Haematol
; 192(3): e84-e87, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33426648
17.
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Br J Haematol
; 195(5): 706-709, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34545952
18.
The benefit of prehabilitation and enhanced recovery in robot-assisted radical prostatectomy and the promising future of these protocols in the field of urologic oncology.
Cancer
; 126(18): 4107-4109, 2020 09 15.
Article
in English
| MEDLINE | ID: mdl-32639580
19.
The investigation and management of follicular lymphoma.
Br J Haematol
; 191(3): 363-381, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32579717
20.
Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab.
Br J Haematol
; 184(3): 462-465, 2019 02.
Article
in English
| MEDLINE | ID: mdl-29363752